Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1992 August; 33(8): 1094–1098.
PMCID: PMC1379449

Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.


In a European multicentre study 40 patients with HBeAg positive chronic hepatitis B virus (HBV) infection were treated with 5 mega units of lymphoblastoid alpha-interferon daily according to the following regimen: a four week primer course, four weeks of rest and a second course lasting 16 to 30 weeks. After 52 weeks of follow up, a response (HBeAg seroconversion and HBV-DNA negativity) was observed in 22 patients (55%). HBsAg seroconversion occurred in five patients (12.5%). One patient exhibited a relapse for serum HBeAg and HBV-DNA after cessation of treatment. According to a response prediction model, the observed response rate was not related to the selection of patients likely to respond. The initial interferon course induced a reduction of the serum HBV-DNA and HBeAg levels of 87% and 18%, respectively, leading to a significantly lower level of viral replication activity at the start of the second longterm course compared with baseline. After 24 weeks of follow up (week 16 of the second course), 19 (48%) patients exhibited a response, 13 (32%) a partial response (HBeAg < 50% of initial level or HBV-DNA negative) and 8 (20%) no response. For eight of the 13 partial responders treatment was stopped at week 24 and viral replication rebounded to pretreatment values. In the last five partial responders prolongation of therapy up to week 38 led to a definite response and HBsAg seroconversion in three of the five patients. The results of this study suggest that a short primer course and prolongation of therapy may help to enhance the response rate of alpha-interferon therapy for chronic hepatitis type B.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (896K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology. 1980 Aug;79(2):195–199. [PubMed]
  • Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med. 1981 Jun;94(6):744–748. [PubMed]
  • Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986 Mar-Apr;6(2):167–172. [PubMed]
  • Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988 Nov;95(5):1318–1325. [PubMed]
  • Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. [PubMed]
  • Brook MG, Chan G, Yap I, Karayiannis P, Lever AM, Jacyna M, Main J, Thomas HC. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ. 1989 Sep 9;299(6700):652–656. [PMC free article] [PubMed]
  • Schalm SW, Heytink RA, van Buuren HR, de Man RA. Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet. 1985 Aug 17;2(8451):358–360. [PubMed]
  • Berk L, Schalm SW, de Man RA, Heytink RA, Berthelot P, Brechot C, Boboc B, Degos F, Marcellin P, Benhamou JP, et al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. J Hepatol. 1992 Mar;14(2-3):305–309. [PubMed]
  • Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989 Nov;10(5):761–763. [PubMed]
  • Garcia G, Smith CI, Weissberg JI, Eisenberg M, Bissett J, Nair PV, Mastre B, Rosno S, Roskamp D, Waterman K, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 1987 Sep;107(3):278–285. [PubMed]
  • Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker-Melman M, Park Y, Waggoner JG, Hoofnagle JH. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology. 1990 Feb;11(2):266–270. [PubMed]
  • Hoofnagle JH. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J Hepatol. 1990;11 (Suppl 1):S100–S107. [PubMed]
  • Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 1988 Aug 6;2(8606):298–302. [PubMed]
  • Thomas HC. The hepatitis B virus and the host response. J Hepatol. 1990;11 (Suppl 1):S83–S89. [PubMed]
  • Fattovich G, Brollo L, Boscaro S, Pontisso P, Giustina G, Criscuolo D, Maladorno D, Alberti A, Realdi G, Ruol A. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol. 1989 Nov;9(3):331–337. [PubMed]
  • Saracco G, Mazzella G, Rosina F, Cancellieri C, Lattore V, Raise E, Rocca G, Giorda L, Verme G, Gasbarrini G, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology. 1989 Sep;10(3):336–341. [PubMed]
  • Carreño V, Porres JC, Mora I, Bartolomé J, Bas C, Gutiez J, Cortés J, Hernández Guio C. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver. 1987 Dec;7(6):325–332. [PubMed]
  • Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet. 1987 Jul 11;2(8550):66–69. [PubMed]
  • Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. J Hepatol. 1987 Aug;5(1):51–58. [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group